Nature immunology
Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy.
Alberto G Conti, Alexander C Evans, Teresa von Linde, Christian Deo T Deguit, Sarah K Whiteside, Alexander J Wesolowski, Charlotte J Imianowski, Yumi Yamashita-Kanemaru, Layla Dahmani, Jack Chapman, Ardon M Pillay, Aws Al-Deka, Randy Greaves, Oliver Burton, Panagiota Vardaka
Published: 202610.1038/s41590-025-02389-z
Abstract
Adoptive T cell therapies are limited by poor persistence of transferred cells. Attempts to enhance persistence have focused on genetic induction of constitutively hyperactivated but potentially oncogenic T cell states. Physiological T cell responses…
Preview only. Read the full abstract at the source